The companies were trialling the angiopoietin2 (Ang2) antibody nesvacumab in combination with their already-marketed Eylea (aflibercept) – but phase 2 results came up short. After the huge ...

Intraocular inflammation occurred more frequently with 8-mg aflibercept (Eylea) compared with what was observed in previous clinical trials among patients with neovascular age-related macular ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) injection 8mg for priority review.